Abstract
A randomized prospective trial was undertaken in adult patients with serious intra-abdominal infections to determine whether a new combination of antibiotic therapy could prove as efficacious as the combination that has been widely used in practice in the recent decade (clindamycin and gentamicin). Three hundred thirty-one patients were randomized in a 2:1 ratio, with the larger number of patients being treated parenterally with piperacillin and tazobactam. The results showed that both the clinical and microbiologic performance of the piperacillin/tazobactam combination was better than that of clindamycin and gentamicin. This clinical equivalence permits overall cost savings without compromising the existing quality of antimicrobial therapy for intra-abdominal infection.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase III
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Abdomen*
-
Abscess / drug therapy
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Appendicitis / drug therapy
-
Bacterial Infections / drug therapy*
-
Bacterial Infections / surgery*
-
Cholangitis / drug therapy
-
Cholecystitis / drug therapy
-
Clindamycin / administration & dosage
-
Combined Modality Therapy
-
Diverticulitis / drug therapy
-
Drug Therapy, Combination / therapeutic use*
-
Female
-
Gentamicins / administration & dosage
-
Humans
-
Male
-
Middle Aged
-
Penicillanic Acid / administration & dosage
-
Peritonitis / drug therapy
-
Piperacillin / administration & dosage
-
Prospective Studies
-
Tazobactam
-
beta-Lactamase Inhibitors*
Substances
-
Gentamicins
-
beta-Lactamase Inhibitors
-
Clindamycin
-
Penicillanic Acid
-
Tazobactam
-
Piperacillin